A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RCMD / refractory cytopenia with multilineage dysplasia

[Related PubMed/MEDLINE]
Total Number of Papers: 72
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RCMD  (>> Co-occurring Abbreviation)
Long Form:   refractory cytopenia with multilineage dysplasia
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation. ANC, GO, Hb, HI-E, HI-N, HI-P, MDS, PLT
2019 Gender disparity in the survival of patients with primary myelodysplastic syndrome. MDS, MDS/MPN, RA, SEER
2019 [Analysis of Cytogenetic Characteristics and Clinical Prognosis in 236 Patients with Myelodysplastic Syndrome]. RA, RARS, RCUD
2018 Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. CMML, MDS, SIAMs
2017 Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. AML, MDS
2017 Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. AML, CK, MDS, TLC, WHO
2017 Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. HSC, HSPCs, MDS, MSCs
2017 DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome. CMML, MDS, RA, RAEB-I, RAEB-II, RARS
2017 Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. MDS, RAEB-1,2, RARS, ROS, TIBC, WHO
10  2017 Myelodysplastic Syndrome Developing Presacral Extramedullary Hematopoiesis with Atypical MRI Findings. BM, CT, MRI
11  2017 p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation. BMBs, BMT, MDS, OS, p53-IR, RAEB-2
12  2017 [Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing]. MDS, MDS-U, OS, RAEB-1, RARS, RCUD
13  2015 A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. MDS, RAEB
14  2015 Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. MDS, RA-RARS, RAEB-1, RAEB-2
15  2015 Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. ESA, HI-E, LR-MDS
16  2015 [Analysis of the karyotype abnormalities and its prognostic in 298 patients with myelodysplastic syndrome]. MDS, MDS-U, RARS, RCUD, WHO
17  2015 [Establishment of Primary Adult MDS Nested Case-Control Study Cohort and Study of Risk Factors Associated with MDS Evolution to Leukemia]. ANC, FISH, LFS, MDS, RA, RARS
18  2014 CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. AML-NOS, MDS, RAEBs
19  2014 Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. AML, HSPCs, MDS, RAEB
20  2014 Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. MDS, PRDX2
21  2014 Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report. CAP, t-AML, t-MDS
22  2013 Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia. BM, ENG, MDS
23  2013 [Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases]. AA, MDS, RCC
24  2013 [Detection of chromosome abnormalities in myelodysplastic syndromes with interval fluorescence in situ hybridization]. CC, FISH, IPSS, MDS, RA, WHO
25  2013 [Relationship between polymorphisms of tumor necrosis factor alpha gene and primary myelodysplastic syndromes]. MDS, SNP, TNF-alpha
26  2012 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. CMML-2, IWG, MDS, RAEB
27  2012 Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome. dUTP, MDS, RA, RAS, RT-PCR, TCR, TIA-1
28  2012 Diagnosis of acquired bone marrow failure syndrome during childhood using the 2008 World Health Organization classification system. AA, BM, RCC
29  2012 Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome. MDS, PCR, RAEB
30  2012 Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. OS
31  2012 Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. MDS, WPSS
32  2012 SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. MDSs, RAEB-1, RARS, RSs
33  2012 [Aplastic anemia complicated with ulcerative colitis]. ATG, BMT, RBC
34  2012 [Sustained remission of blastic plasmacytoid dendritic cell neoplasm with ABVD chemotherapy]. ASD-Ch, MPO
35  2012 [The role of bone marrow pathology in diagnosis and differential diagnosis of refractory cytopenia of children]. AA, RCC
36  2011 Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. CI, MDS, OR, RAEB
37  2011 Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. ISCN, MDS, RA, RAEB-1, RAEB-2, RARS, RCMD-RS
38  2011 Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. FCSS, IPSS, MDS, WPSS
39  2011 Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. MDS
40  2011 [Cytogenetic peculiarity of chromosomal abnormalities in myelodisplastic syndromes in childhood]. Chr, MDS, RA, RAEB
41  2011 [Expression of CD133 in the bone marrow of patients with myelodysplastic syndrome and its clinical significance]. AA, MDS, RAEB
42  2010 Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. HI, MDS
43  2010 Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. MDS
44  2010 Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure. Bz, MDS, MDS-Eo, MDS-U, OR, RA, RAEB, RCUD
45  2010 Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. ICT, MDS, RA, RARS, RBC
46  2010 [The value of flow cytometry for the differential diagnosis between refractory cytopenia with multiple dysplasia and aplastic anemia]. AA, FCM, MDS
47  2009 Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. aGVHD, BM, cGVHD, CI, CMML, CR, DFS, HSCT, MA, MDS, MDS-NOS, MDS-U, NMA, OS, PBSC, RA, RCMD-RS, TBI, TRM, UCB, URD
48  2009 Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. MDS, RA/RARS, RAEB-1, RAEB-2
49  2009 Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome. MDS, RA, RAEB-1, RAEB-2, RARS, Th1, Th2
50  2009 Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). MDS, RA
51  2009 [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome]. MDS, RA, RARS, rhEPO
52  2009 [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts]. BM, ICUS, MDS, MDS-U, PB, RA, RARS
53  2009 [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification]. IPSS, MDS, NAC, OS, RAEB, WPSS
54  2008 Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. IPSS, MDSs, RA, RAEB-1, RS, WHO
55  2008 [An analysis of prognostic factors in 80 myelodysplastic syndrome]. IPSS, MDS, RA, RAEB
56  2008 [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome]. FAB, IPSS, MDS, RA/RAS, WHO
57  2008 [WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome]. FISH, IPSS, MDS, MDS-U, RA, RAEB, RAS
58  2007 Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. dys Mgk, FAB, LFS, OS, OS, RA, WHO
59  2007 Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. CN, IPSS, LOH, MDS, RA, RAEB, RARS, RCMD-RS, SNP, UPD
60  2006 Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. FAB, MDS, RA, RARS, RCMD-RS, WHO
61  2006 Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. AML, BM, FAB, IPSS, LFS, MDS, OS, RAEB-I, WHO
62  2006 Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. AA, AML, BM, MDS, WHO
63  2006 Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. AML, FAB, MDS, RA, RAEB, RARS, RCMD-RS, WHO
64  2006 Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. MDS, RCMD-RS
65  2005 Classification of myeloid neoplasms: a comparative review. AML, MDS, WHO
66  2005 The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. HUMARA, IDS, MDS, XCIP
67  2004 Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. IPSS, MDS, SCT
68  2004 Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. BM, MDS, RA, RAEB
69  2004 [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification]. PMDS
70  2004 [Refractory anemia (RA) and refractory cytopenia with multilineage dysplasia (RCMD) in WHO classification: comparison between Japanese and German cases]. RA
71  2003 A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. AML, FAB, FISH, MDS, RA
72  2003 Refractory Thrombocytopenia with Multilineage Dysplasia: A Rare Type of Myelodysplastic Syndrome. AML, MDS, RT, WHO